SRP72

Across TCGA pan-cancer cohorts, SRP72 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SRP72’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where SRP72 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SRP72 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

PDAC, LUAD, and LSCC are the cancer types where SRP72 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SRP72 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	All	−0.940	<.001	9	view →
LUAD	Male	III,IV	+0.590	<.001	9	view →
LSCC	Female	II,III,IV	+0.539	<.001	9	view →
COAD	Male	III,IV	+0.360	<.001	9	view →
HNSC	Male	All	+0.145	.001	8	view →
CCRCC	Male	II,III,IV	+0.144	<.001	6	view →
OV	All	All	+0.810	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SRP72–PDAC

Open the PDAC breakdown →